Literature DB >> 17828498

Cloning, expression and polyclonal antibody preparation of the asialoglycoprotein receptor of Marmota himalayan.

Yan Yang1, Huang Huang, Zhenghua Zhang, Baoju Wang, Yongjun Tian, Mengji Lu, Dongliang Yang.   

Abstract

The objective of this study is to express the carbohydrate recognition domain (CRD) of the asialoglycoprotein receptor (ASGPR) H1 and H2 subunits of Marmota himalayan in vitro, and develop polyclonal antibodies against the recombinant proteins. RT-PCR was used to amplify ASGPR CRDH1 and CRDH2 from the liver tissue of Marmota himalayan. The products of amplification were subcloned into prokaryotic expression vector pRSET-B, and expressed in E.coli BL21(DE3)plysS. The recombinant proteins were purified using Ni-NTA spin column. The purified proteins were inoculated into BALB/c mice to develop polyclonal antibodies. The sensitivity and specificity of antibodies were evaluated by enzyme-linked immunosorbent assay (ELISA), Western blotting and immunohistochemical staining (IHC). The polyclonal antibodies showed high sensitivity and specificity against both denaturated and native ASGPR proteins. We successfully amplified and expressed the ASGPR CRDs of Marmota himalayan. The nucleic sequences of ASGPR CRDH1 and CRDH2 of Marmota himalayan have been submitted to Genbank and the sequence ID are DQ 845465 and DQ845466, respectively. The proteins and antibodies prepared can be used for targeting gene therapy in a new animal model-Marmota Himalayan-for the research of infectious diseases of hepatitis viruses and liver cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17828498     DOI: 10.1007/s11596-007-0415-4

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  12 in total

1.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase.

Authors:  C Tuerk; L Gold
Journal:  Science       Date:  1990-08-03       Impact factor: 47.728

Review 2.  Delivery systems for gene therapy.

Authors:  G Y Wu; C H Wu
Journal:  Biotherapy       Date:  1991

3.  Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA.

Authors:  Songchuan Guo; Nuska Tschammer; Sulma Mohammed; Peixuan Guo
Journal:  Hum Gene Ther       Date:  2005-09       Impact factor: 5.695

4.  A small viral RNA is required for in vitro packaging of bacteriophage phi 29 DNA.

Authors:  P X Guo; S Erickson; D Anderson
Journal:  Science       Date:  1987-05-08       Impact factor: 47.728

5.  Role of the asialoglycoprotein receptor in binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes.

Authors:  Bertrand Saunier; Miriam Triyatni; Luca Ulianich; Padma Maruvada; Paul Yen; Leonard D Kohn
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

Review 6.  The asialoglycoprotein receptor: relationships between structure, function, and expression.

Authors:  R J Stockert
Journal:  Physiol Rev       Date:  1995-07       Impact factor: 37.312

7.  An experimental transmission of woodchuck hepatitis virus to young Chinese marmots.

Authors:  Z H Jin; G L Zhao; S S Ziong; P Y Kou; L L Ma; H T Chen; J Y Qi; Q J Ba; K Mai
Journal:  Hepatology       Date:  1988 Mar-Apr       Impact factor: 17.425

8.  Crystal structure of the carbohydrate recognition domain of the H1 subunit of the asialoglycoprotein receptor.

Authors:  M Meier; M D Bider; V N Malashkevich; M Spiess; P Burkhard
Journal:  J Mol Biol       Date:  2000-07-21       Impact factor: 5.469

Review 9.  Evaluation of new approaches to prophylactic and therapeutic vaccinations against hepatitis B viruses in the woodchuck model.

Authors:  M Lu; M Roggendorf
Journal:  Intervirology       Date:  2001       Impact factor: 1.763

10.  Therapeutic vaccination of woodchucks against chronic woodchuck hepatitis virus infection.

Authors:  S Hervás-Stubbs; J J Lasarte; P Sarobe; J Prieto; J Cullen; M Roggendorf; F Borrás-Cuesta
Journal:  J Hepatol       Date:  1997-10       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.